DK1979356T3 - Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer - Google Patents

Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer

Info

Publication number
DK1979356T3
DK1979356T3 DK06831731.2T DK06831731T DK1979356T3 DK 1979356 T3 DK1979356 T3 DK 1979356T3 DK 06831731 T DK06831731 T DK 06831731T DK 1979356 T3 DK1979356 T3 DK 1979356T3
Authority
DK
Denmark
Prior art keywords
carbonylaminopyrrolopyrazoles
powerful
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
DK06831731.2T
Other languages
English (en)
Inventor
Liming Dong
Chuangxing Guo
Yufeng Hong
Mary Catherine Johnson
Susan Elizabeth Kephart
Haitao Li
Indrawan James Mcalpine
Jayashree Girish Tikhe
Anle Yang
Junhu Zhang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1979356T3 publication Critical patent/DK1979356T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK06831731.2T 2005-12-21 2006-12-12 Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer DK1979356T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75334905P 2005-12-21 2005-12-21
US86493206P 2006-11-08 2006-11-08
PCT/IB2006/003646 WO2007072153A2 (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

Publications (1)

Publication Number Publication Date
DK1979356T3 true DK1979356T3 (da) 2013-11-18

Family

ID=38189022

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06831731.2T DK1979356T3 (da) 2005-12-21 2006-12-12 Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer

Country Status (26)

Country Link
US (1) US7884117B2 (da)
EP (1) EP1979356B1 (da)
JP (1) JP4635089B2 (da)
KR (1) KR101029167B1 (da)
AP (1) AP2369A (da)
AU (1) AU2006327866B2 (da)
BR (1) BRPI0620354A2 (da)
CA (1) CA2634381C (da)
CR (1) CR10094A (da)
CU (1) CU23751B7 (da)
DK (1) DK1979356T3 (da)
EA (1) EA015513B1 (da)
EC (1) ECSP088558A (da)
ES (1) ES2435405T3 (da)
GE (1) GEP20104974B (da)
HR (1) HRP20130976T1 (da)
IL (1) IL191776A (da)
MA (1) MA30076B1 (da)
ME (1) ME00006B (da)
MY (1) MY151455A (da)
NO (1) NO20082482L (da)
NZ (1) NZ568692A (da)
PL (1) PL1979356T3 (da)
PT (1) PT1979356E (da)
RS (2) RS20080281A (da)
WO (1) WO2007072153A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
DK2620428T3 (da) * 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
WO2012065935A1 (en) 2010-11-17 2012-05-24 F. Hoffmann-La Roche Ag Methods of treating tumors
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
KR20140135198A (ko) 2012-03-16 2014-11-25 에프. 호프만-라 로슈 아게 Pak1 억제제로 흑색종을 치료하는 방법
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
CN112007045B (zh) 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JP6690543B2 (ja) 2014-10-31 2020-04-28 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物
AU2015371251B2 (en) * 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
US10273252B2 (en) 2015-06-15 2019-04-30 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
WO2020100944A1 (ja) 2018-11-14 2020-05-22 宇部興産株式会社 ジヒドロピロロピラゾール誘導体
WO2020140098A1 (en) * 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
EP3956446A1 (en) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025078334A1 (en) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4555547B2 (ja) * 2000-08-10 2010-10-06 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物
EP1527074A1 (en) 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0229526D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
AU2004276341B2 (en) * 2003-09-23 2011-04-14 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
KR100919343B1 (ko) 2005-01-10 2009-09-25 화이자 인코포레이티드 키네이스 억제제로서 피롤로피라졸

Also Published As

Publication number Publication date
ECSP088558A (es) 2008-07-30
NZ568692A (en) 2011-07-29
WO2007072153A2 (en) 2007-06-28
HK1128290A1 (en) 2009-10-23
JP2009520805A (ja) 2009-05-28
CA2634381A1 (en) 2007-06-28
EA015513B1 (ru) 2011-08-30
AP2369A (en) 2012-02-29
AU2006327866B2 (en) 2012-06-14
CU20080115A7 (es) 2010-08-30
MEP0808A (xx) 2010-02-10
JP4635089B2 (ja) 2011-02-16
WO2007072153A8 (en) 2008-08-14
IL191776A (en) 2013-03-24
IL191776A0 (en) 2008-12-29
US7884117B2 (en) 2011-02-08
CU23751B7 (es) 2012-01-31
CA2634381C (en) 2011-03-08
RS53029B (sr) 2014-04-30
ME00006B (me) 2010-02-10
MA30076B1 (fr) 2008-12-01
AU2006327866A1 (en) 2007-06-28
EA200801291A1 (ru) 2008-12-30
GEP20104974B (en) 2010-04-26
AP2008004506A0 (en) 2008-06-30
US20090318440A1 (en) 2009-12-24
ES2435405T3 (es) 2013-12-19
HRP20130976T1 (hr) 2013-11-22
WO2007072153A3 (en) 2007-10-25
NO20082482L (no) 2008-07-02
EP1979356B1 (en) 2013-09-18
KR101029167B1 (ko) 2011-04-12
PL1979356T3 (pl) 2014-01-31
CR10094A (es) 2008-08-01
EP1979356A2 (en) 2008-10-15
MY151455A (en) 2014-05-30
PT1979356E (pt) 2013-11-21
KR20080080567A (ko) 2008-09-04
RS20080281A (sr) 2009-09-08
BRPI0620354A2 (pt) 2011-11-08

Similar Documents

Publication Publication Date Title
FR21C1019I2 (fr) Inhibiteurs de kinase de type biaryl-meta-pyrimidine
NL300935I2 (nl) guselkumab.
LTC1907382I2 (lt) Nitrokatechnolio dariniai, kaip COMT inhibitoriai
DK1838718T3 (da) Pyrrolopyrazoler, potente kinase inhibitorer
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
DK1704145T3 (da) Selektive kinaseinhibitorer
DE602006011787D1 (de) Ker
DK1860941T3 (da) Biphenyl-N-(4-pyridyl)methylsufonamider
NO20051199D0 (no) Rorhandteringsutstyr.
DK1943243T3 (da) Kinase-inhibitorer
DE112005003586A5 (de) Bohrfutter
DK1713805T3 (da) Kinaseinhibitorer
DK1848727T3 (da) Ibandronat polymorf b
NO20053362L (no) Syklofuge.
ATE520664T1 (de) Tyrosinkinase-hemmer
ATE418545T1 (de) Nnrt-inhibitoren
ITMI20050051A1 (it) Fotodiodio organico di poli-9,9-diottil-fluorene
DE502006006543D1 (de) Werkzeughalter
AT501523A3 (de) Estrich
AT501968A3 (de) Mitführhilfe
DE602006019301D1 (de) Kinaseinhibitoren
ES1060125Y (es) Peana para parasoles.
DE602005008061D1 (de) Kinaseinhibitoren
SK4225U (sk) Nátierka, ktorej základ tvorí sója